Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the design of the DASL-HiCAP trial in high-risk prostate cancer.
Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, a clinical professor in Medical Oncology at the University College Dublin, discusses the design of the DASL-HiCAP trial in high-risk prostate cancer.
The ongoing phase 3 study is evaluating the addition of darolutamide (Nubeqa) to androgen deprivation therapy and definitive or salvage radiation in men with high-risk prostate cancer.
Participants will be randomized 1:1 to receive darolutamide for 96 weeks or placebo, McDermott says.
Patients will be stratified by factors such as pelvic nodal status, prior exposure to docetaxel, and prior prostatectomy, says McDermott.
The trial, which was initially designed in Australia, will enroll 1100 patients from the United States, Europe, Canada, Australia, and New Zealand, concludes McDermott.